Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15, 2024
Regeneron appeals legal decision after judge refuses to block aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM) becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.